Skip to content

The clinical study of Sleepaxa eyewear in the preventive treatment of common migraine.

Clinical validation of the efficacy of Sleepaxa eyewear in the preventive treatment of common migraine. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070580
Enrollment
30
Registered
2024-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G430- Migraine without aura

Interventions

Intervention1: Sleepaxa eyewear: Wear Sleepaxa Migraine Glasses just like regular eyeglasses for 28 days. They can be worn throughout the day to provide continuous protection against migraine triggers

Sponsors

Sleepaxa Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with a history of migraine without aura for at least 6 months prior to the screening visit for the study 2.Patients with light sensitivity and eye fatigue due to migraine 3.Patients experiencing 2-6 migraine attacks per month, but not more than 15 headache days per month 4.Male or female patients aged 18 to 60 years (both inclusive) 5.Patients willing to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients have more than 15 headache days per month or less than 2 migraine attacks per month 2. Patients have more than 6 attacks per year of migraine with aura 3. Pregnant women or nursing mothers 4. Women of child-bearing potential & all men not willing to follow a reliable & effective contraceptive measure during the course of the study 5. Patients headache attacks are associated with or attributable to an identifiable cause such as premenstrual period a disease of eye ear or nose a neurological disease or a psychiatric illness 6. Any known refractive errors.

Design outcomes

Primary

MeasureTime frame
1. Assessment of changes in the frequency of migraine headaches by using migraine diary/headache diary.Timepoint: Baseline, Day 7, Day 14, Day 28

Secondary

MeasureTime frame
1.Assessment of changes in the intensity and duration of migraine headaches from baseline to end of the study. 2.Patient-reported assessments of changes in eye fatigue and light sensitivity using Visual Analog Scales (VAS) from screening to end of the study. 3.Proportion of patients achieving a greater than or equal to 50% reduction in migraine frequency from screening to end of the study. 4.Assessment of changes in perceived stress levels measured by the Perceived Stress Scale (PSS) from baseline to end of the study. 5.Assessment of changes in mood measured by the Profile of Mood States (POMS) questionnaire from baseline to end of the study. Timepoint: Screening, Baseline, Day 7, Day 14, Day 28

Countries

India

Contacts

Public ContactMr Suraj Arun Dubey

Mprex Healthcare Pvt. Ltd.

drgayatri@mprex.in8554912644

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026